Scynexis (SCYX) Net Income towards Common Stockholders (2013 - 2026)

Scynexis (SCYX) reported Net Income towards Common Stockholders of -$16.4 million for Q1 2026, down 204.28% on a YoY basis from $15.7 million in Q1 2025, and down 233.82% quarter-over-quarter from $12.3 million in Q4 2025.

Scynexis (SCYX) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends

Scynexis has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$16.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 204.28% year-over-year to -$16.4 million; the trailing twelve-month figure through Mar 2026 stood at -$19.6 million (up 27.57% YoY), and the FY2025 full-year result was -$8.6 million, up 59.56% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$16.4 million, down from $12.3 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $122.3 million in Q2 2023, with the low at -$33.9 million in Q1 2023.
  • Historically, Net Income towards Common Stockholders has averaged -$2.5 million across 5 years, with a median of -$6.9 million in 2025.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 4789.92% — and 2023, when it soared 1016.15%.
  • Scynexis' Net Income towards Common Stockholders stood at -$14.4 million in 2022, then slumped by 35.56% to -$19.5 million in 2023, then surged by 77.32% to -$4.4 million in 2024, then soared by 376.52% to $12.3 million in 2025, then slumped by 233.82% to -$16.4 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$16.4 million (Q1 2026), $12.3 million (Q4 2025), and -$8.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn 366.00 Mn
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn 601.00 Mn
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn 274.90 Mn
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn 1.99 Mn
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn 197.90 Mn
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn 57.00 Mn
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn -66.53 Mn
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn 118.42 Mn
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn -92.12 Mn
10 Scynexis 216.06 Mn 156.80 Mn - -16.40 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -16.40 Mn
Dec 31, 2025 12.26 Mn
Sep 30, 2025 -8.59 Mn
Jun 30, 2025 -6.89 Mn
Mar 31, 2025 -5.39 Mn
Dec 31, 2024 -4.43 Mn
Sep 30, 2024 -2.81 Mn
Jun 30, 2024 -14.46 Mn
Mar 31, 2024 411,000.00
Dec 31, 2023 -19.55 Mn
Sep 30, 2023 -1.76 Mn
Jun 30, 2023 122.26 Mn
Mar 31, 2023 -33.88 Mn
Dec 31, 2022 -14.42 Mn
Sep 30, 2022 -29.58 Mn
Jun 30, 2022 -13.35 Mn
Mar 31, 2022 -5.45 Mn
Dec 31, 2021 -29.28 Mn
Sep 30, 2021 -605,000.00
Jun 30, 2021 1.66 Mn